TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical-stage company pioneering immuno-oncology and RNA therapeutics for high-risk and advanced cancers, announced the retirement of Chief Financial Officer Tom Fitzgerald, effective immediately. Fitzgerald, who has served as CFO since July 2018 and also as a director, will resign from both roles but will continue to provide transition services to the company. The board has appointed John Tattory as interim CFO, also effective immediately.
Tattory brings more than 25 years of financial and operational management experience across the pharmaceutical, medical device, and biotechnology sectors. His career includes roles at Ernst & Young LLP, Bristol-Myers Squibb, Tyco International, Cerapedics, and Windtree Therapeutics. Currently, he serves as a managing director at Stout Risius Ross, where he provides consulting CFO services primarily to privately held life science companies. This depth of experience in financial leadership and life sciences is expected to support TransCode as it advances its clinical programs.
The leadership change comes at a critical time for TransCode, which is focused on developing innovative treatments for metastatic cancers. The company’s lead therapeutic candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis. In addition, TransCode has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells. The appointment of an interim CFO with Tattory's background may provide stability and financial expertise as the company navigates the complex regulatory and funding landscape of oncology drug development.
For investors and industry observers, the transition highlights the importance of strong financial stewardship in clinical-stage biotechnology companies. TransCode’s ability to maintain momentum in its research and development efforts while effectively managing its financial resources will be crucial. The company’s progress, including updates on its pipeline, can be followed in its newsroom at https://nnw.fm/RNAZ. The full press release detailing the leadership change is available at https://nnw.fm/8G3ik.
NetworkNewsWire, a specialized communications platform focused on financial news and content distribution, published the announcement. As part of its services, NetworkNewsWire provides access to a vast network of wire solutions, article syndication to over 5,000 outlets, press release enhancement, and social media distribution. For more information, visit https://www.NetworkNewsWire.com. Terms of use and disclaimers are available at https://www.NetworkNewsWire.com/Disclaimer.
The retirement of a long-serving CFO and the appointment of an interim replacement can have implications for a company’s strategic direction and investor confidence. Tattory’s extensive experience in life sciences and his current role at Stout Risius Ross, where he advises private life science companies, may bring fresh perspectives to TransCode’s financial strategy. As the company continues to develop its RNA therapeutics, effective financial management will be key to funding clinical trials and achieving regulatory milestones. Stakeholders will be watching closely to see how the transition affects TransCode’s operations and its ability to deliver on its promising pipeline.
